Abstract:Diffuse low-grade gliomas account for approximately 20% of all primary brain tumors, they arise from glial cells and show infiltrative growth without histological features of malignancy. Mutations of the IDH1 and IDH2 genes constitute a reliable molecular signature of low-grade gliomas and are the earliest driver mutations occurring during gliomagenesis, representing a relevant biomarker with diagnostic, prognostic, and predictive value. IDH mutations induce a neomorphic enzyme that converts α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate, which leads to widespread effects on cellular epigenetics and metabolism. Currently, there are no approved molecularly targeted therapies and the standard treatment for low-grade gliomas consists of radiation therapy and chemotherapy, with rising concern about treatment-related toxicities. Targeting D-2-hydroxyglutarate is considered a novel attractive therapeutic approach for low-grade gliomas and the insights from clinical trials suggest that mutant-selective IDH inhibitors are the ideal candidates, with a favorable benefit/risk ratio. A pivotal question is whether blocking IDH neomorphic activity may activate alternative oncogenetic pathways, inducing acquired resistance to IDH inhibitors. Based on this rationale, combination therapies to enhance the antitumor activity of IDH inhibitors and approaches aimed at exploiting, rather than inhibiting, the metabolism of IDH-mutant cancer cells, such as poly (adenosine 5′-diphosphate-ribose) polymerase inhibitors, are emerging from preclinical research and clinical trials. In this review, we discuss the pivotal role of IDH mutations in gliomagenesis and the complex interactions between the genomic and epigenetic landscapes, providing an overview of how, in the last decade, therapeutic approaches for low-grade gliomas have evolved.

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH1/2 Mutations Target a Key Hallmark of Cancer by Deregulating Cellular Metabolism in Glioma

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

IDH Mutations Associated Impact on Related Cancer Epidemiology and Subsequent Effect Toward HIF-1α

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Immune Heterogeneity of IDH Glioma Subtypes

Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype

Therapies for IDH-Mutant Gliomas

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

Metabolism of glioma and IDH1/IDH2 mutations

Local and Systemic Effects of IDH Mutations on Primary Glioma Patients.

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma

Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency